Sandoz Iberia

About Sandoz Iberia

At Sandoz, our purpose is to help patients and physicians honor their commitment to better health and aspire to be the world's leading and most valued generics and biosimilars company. The company's origins date back to Basel, Switzerland, in 1886. We are proud of our long history, which is today synonymous with quality, reliability, and innovation. We are present in more than 100 countries worldwide, with approximately 1,000 molecules in our global portfolio and 500 million patients benefited from our products in 2021. We are the world's No. 1 generics market by net sales, the second in biosimilars, and the leading generics company in Europe. We are working to continue growing and reaching more patients with affordable, high-quality medicines. The more we grow, the more we can invest in finding more innovative ways to facilitate and increase access to health. Sandoz Industrial Products SA, with two production plants in Spain, is one of the world's leading producers of semi-synthetic antibiotics. The Les Franqueses plant, which began operations over 50 years ago, is one of the largest plants in the world specializing in the production of semi-synthetic penicillins with an annual production of about 4000 tons. The Palafolls plant, acquired in 2003, is dedicated to the manufacture of sterile antibiotics, with an annual production of 108 tons. We do all this through our team and our culture, which is based on integrity and inclusion. Together, we work on solid business performance and drive the development of our products and value projects. Your data may be extracted for the sole purpose of carrying out monitoring corresponding to pharmacovigilance regulations.